Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging

The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a d...

Full description

Saved in:
Bibliographic Details
Main Authors YANG DAVID J, OH CHANG-SOK, BRYANT JERRY L, YU DONG-FANG
Format Patent
LanguageChinese
English
Published 16.03.2011
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention provides, in a general sense, a new labeling strategy employing compounds that are are N2S2 chelates conjugated to a targeting ligand, wherein the targeting ligand is a disease cell cycle targeting compound, a tumor angiogenesis targeting ligand, a tumor apoptosis targeting ligand, a disease receptor targeting ligand, amifostine, angiostatin, monoclonal antibody C225, monoclonal antibody CD31, monoclonal antibody CD40, capecitabine, COX-2, deoxycytidine, fullerene, herceptin, human serum albumin, lactose, leuteinizing hormone, pyridoxal, quinazoline, thalidomide, transferrin, or trimethyl lysine. The present invention also pertains to kits employing the compounds of interest, and methods of assessing the pharmacology of an agent of interest using the present compounds.
Bibliography:Application Number: CN20101295764